Do cardiologists from the AFFIRM generation treat AF less aggressively than the EAST-AFNET generation? Bob Harrington and Jonathan Piccini discuss this and upcoming trials on atrial fibrillation.
This podcast is intended for healthcare professionals only.
To read a transcript or to comment, visit:
https://www.medscape.com/author/bob-harrington
A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation (AFFIRM)
https://www.nejm.org/doi/full/10.1056/NEJMoa021328
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)
https://www.nejm.org/doi/10.1056/NEJMoa2019422
Early AF Rhythm-Control Advantage Climbs With Comorbidity Burden: EAST-AFNET4
https://www.medscape.com/viewarticle/979627
Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation (CHANGE-AFIB)
https://clinicaltrials.gov/ct2/show/NCT05130268
Generalizability of the EAST‐AFNET 4 Trial: Assessing Outcomes of Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation
https://doi.org/10.1161/JAHA.121.024214
Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients
A Nationwide Propensity Score–Weighted Study
https://doi.org/10.7326/M21-4798
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology
https://www.medscape.com/twic
Questions or feedback, please contact